Clinical trial registry record

Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Withdrawn.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 22, 2022.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04407390
Last registry update
September 22, 2022
Status
Withdrawn
Phase
Phase 2
Sponsor
University of Copenhagen
Enrollment
0
Countries
Denmark
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
0
Population
ALL · 70 Years
Duration
2020-06-01 to 2022-05-01
Intervention
Nicotinamide riboside; Placebo
Comparator
Control
Outcomes measured
Hypoxic respiratory failure — Day 1; Hypoxic respiratory failure — Day 7; Hypoxic respiratory failure — Day 14; Hypoxic respiratory failure — Day 90; Mortality — Day 1; Mortality — Day 7; Mortality — Day 14; Mortality — Day 90; Sepsis — Day 1; Sepsis — Day 7; Sepsis — Day 14; Sepsis — Day 90; Circulatory failure — Day 1; Circulatory failure — Day 7; Circulatory failure — Day 14; Circulatory failure — Day 90; Days in hospital — Day 1; Days in hospital — Day 7; Days in hospital — Day 14; Days in hospital — Day 90
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • NAD metabolism · 100%Title contains controlled term: nicotinamide riboside. Abstract contains controlled term: nad+, nicotinamide riboside. Source terminology contains: nicotinamide riboside. Title supplies longevity context: elderly. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

nad metabolism
Open primary sourceExport JSON